Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of:
* Advanced solid tumor that is no longer responding to therapies OR
* Advanced or metastatic NSCLC that has previously been treated with erlotinib or gefitinib
ECOG Performance Status 0-1
Adequate organ and bone arrow function as defined by hematological and serum chemistry limits
At least 18 years old
Both men and women must practice adequate contraception
Informed consent
You may not be if
Restriction of some therapies/medications within specific timeframes prior to enrollment and during the study including prior therapy with PI3K, cytotoxic chemotherapy, biologic agents, nitrosoureas or mitomycin C, small-molecule kinase inhibitors, non-cytotoxic hormonal agents
Erlotinib intolerant
Taking oral corticosteroids chronically or \> 1 mg/day warfarin
Not recovered from the toxic effects of prior therapy
History of diabetes mellitus and an HgbA1c \> 7%
Uncontrolled intercurrent illness
Pregnant or breastfeeding
Congestive heart failure, unstable angina, or a myocardial infarction within 3 months of entering the study.
HIV positive
Diagnosis of another malignancy may exclude subject from study
Clareo Health | Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors
